All Updates

All Updates

icon
Filter
Management news
Cyrus Biotechnology spins out Levitate Bio to extend Cyrus platform to biopharmaceutical industry
AI Drug Discovery
Jun 11, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 11, 2024

Cyrus Biotechnology spins out Levitate Bio to extend Cyrus platform to biopharmaceutical industry

Management news

  • AI-driven protein-based drug developer Cyrus Biotechnology is spinning out a biotechnology firm, Levitate Bio, transitioning its software, services, and IT operations. This development is expected to expand the Cyrus platform's reach across biopharma.

  • Following the transition, Levitate Bio will be wholly owned by the Rosetta Commons Foundation (RCF) and led by Cyrus’ former director of engineering. Cyrus continues to benefit from the platform, and Levitate Bio will work to build a broader market by attracting new customers and expanding the range of available services.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.